Janus Kinase (JAK) Inhibitors- Pipeline Insight, 2022
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Janus Kinase (JAK) Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Janus Kinase (JAK) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Janus Kinase (JAK) Inhibitors: Overview
Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway. These inhibitors have therapeutic application in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis. There is interest in their use for various skin conditions. JAK3 inhibitors are attractive as a possible treatment of various autoimmune diseases since its functions is mainly restricted to lymphocytes. Development for a selective JAK3 inhibitors are ongoing. Cytokines play key roles in controlling cell growth and the immune response. Many cytokines function by binding to and activating type I and type II cytokine receptors. These receptors in turn rely on the Janus kinase (JAK) family of enzymes for signal transduction. Hence drugs that inhibit the activity of these Janus kinases block cytokine signalling. More specifically, Janus kinases phosphorylate activated cytokine receptors. These phosphorylated receptors in turn recruit STAT transcription factors which modulate gene transcription
This segment of the Janus Kinase (JAK) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Janus Kinase (JAK) Inhibitors Emerging Drugs
Further product details are provided in the report……..
Janus Kinase (JAK) Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Janus Kinase (JAK) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Janus Kinase (JAK) Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Janus Kinase (JAK) Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Janus Kinase (JAK) Inhibitors drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Janus Kinase (JAK) Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Janus Kinase (JAK) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Janus Kinase (JAK) Inhibitors: Overview
Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway. These inhibitors have therapeutic application in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis. There is interest in their use for various skin conditions. JAK3 inhibitors are attractive as a possible treatment of various autoimmune diseases since its functions is mainly restricted to lymphocytes. Development for a selective JAK3 inhibitors are ongoing. Cytokines play key roles in controlling cell growth and the immune response. Many cytokines function by binding to and activating type I and type II cytokine receptors. These receptors in turn rely on the Janus kinase (JAK) family of enzymes for signal transduction. Hence drugs that inhibit the activity of these Janus kinases block cytokine signalling. More specifically, Janus kinases phosphorylate activated cytokine receptors. These phosphorylated receptors in turn recruit STAT transcription factors which modulate gene transcription
- Janus kinase (JAK) inhibitors are a new addition in the armamentarium of drugs in the treatment of autoimmune dermatoses. They have proven to be valuable in treating a variety of inflammatory dermatoses with lesser side effects compared to their biological counterparts.
- Janus kinase (JAK) inhibitors are small molecules approximately 400 Da that could be administrated as oral medicines. In addition, they are easy to reach the inside of cells and directly inhibit intracellular signaling molecules.
- JAK inhibitors belong to a family of medicine called DMARDs (disease-modifying antirheumatic drugs). Thre JAK inhibitors, baricitinib (Olumiant), tofacitinib (Xeljanz), and upadacitinib (Rinvoq), are approved by the FDA to treat rheumatoid arthritis.
This segment of the Janus Kinase (JAK) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Janus Kinase (JAK) Inhibitors Emerging Drugs
- Gusacitinib - Asana BioSciences
Further product details are provided in the report……..
Janus Kinase (JAK) Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Janus Kinase (JAK) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Janus Kinase (JAK) Inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Janus Kinase (JAK) Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Janus Kinase (JAK) Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Janus Kinase (JAK) Inhibitors drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Janus Kinase (JAK) Inhibitors R&D. The therapies under development are focused on novel approaches for Janus Kinase (JAK) Inhibitors.
- June 2020: Gilead Sciences and Galapagos announced new analyses from two clinical trials evaluating filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with psoriatic arthritis (PsA). The data from the double-blind, placebo-controlled, Phase 2 EQUATOR study and the EQUATOR-2 open-label extension study demonstrate filgotinib’s durable efficacy and consistent safety profile in people with active PsA, and showed rapid and sustained reductions in inflammatory biomarkers in patients with moderate to severe PsA. The new analyses were presented at the European League against Rheumatism, EULAR, European E-Congress of Rheumatology 2020.
- Janus Kinase (JAK) Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Janus Kinase (JAK) Inhibitors drugs?
- How many Janus Kinase (JAK) Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Janus Kinase (JAK) Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Janus Kinase (JAK) Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Janus Kinase (JAK) Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Japan Tobacco/LEO Pharma
- AbbVie
- Incyte Corporation
- Asana BioSciences
- Suzhou Zelgen Biopharmaceuticals
- Gusacitinib
Introduction
Executive Summary
Janus Kinase (JAK) Inhibitors: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Janus Kinase (JAK) Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Janus Kinase (JAK) Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Janus Kinase (JAK) Inhibitors Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
• Comparative Analysis
Gusacitinib - Asana BioSciences
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Janus Kinase (JAK) Inhibitors Key Companies
Janus Kinase (JAK) Inhibitors Key Products
Janus Kinase (JAK) Inhibitors- Unmet Needs
Janus Kinase (JAK) Inhibitors- Market Drivers and Barriers
Janus Kinase (JAK) Inhibitors- Future Perspectives and Conclusion
Janus Kinase (JAK) Inhibitors Analyst Views
Janus Kinase (JAK) Inhibitors Key Companies
Appendix
Executive Summary
Janus Kinase (JAK) Inhibitors: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Janus Kinase (JAK) Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Janus Kinase (JAK) Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Janus Kinase (JAK) Inhibitors Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
• Comparative Analysis
Gusacitinib - Asana BioSciences
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Janus Kinase (JAK) Inhibitors Key Companies
Janus Kinase (JAK) Inhibitors Key Products
Janus Kinase (JAK) Inhibitors- Unmet Needs
Janus Kinase (JAK) Inhibitors- Market Drivers and Barriers
Janus Kinase (JAK) Inhibitors- Future Perspectives and Conclusion
Janus Kinase (JAK) Inhibitors Analyst Views
Janus Kinase (JAK) Inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Janus Kinase (JAK) Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Janus Kinase (JAK) Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Janus Kinase (JAK) Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Janus Kinase (JAK) Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
